Form 13-F position report

VERTEX PHARMACEUTICALS INC

Reported by Provident Investment Management Inc

VRTX CUSIP 92532F100 Manager CIK 0001076964

Reported 131,577 shares, down 9,151 (6.5%) from the prior quarter.

Reported value -1.6%; share count -6.5% vs. the prior quarter.

Reduced
% of reported 13F value 6.89% This manager · Q3 2026
Shares 131,577 Quarter-end amount reported
Reported value $68,789,881 Fair value at quarter end
Consecutive quarters held 22 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 40665000
2022-03-31 48883000
2022-06-30 47722000
2022-09-30 46913000
2022-12-31 46414743
2023-03-31 51370273
2023-06-30 57090007
2023-09-30 56044908
2023-12-31 65232198
2024-03-31 66933851
2024-06-30 74930517
2024-09-30 72322265
2024-12-31 62445078
2025-03-31 75789487
2025-06-30 70656356
2025-09-30 60079926
2025-12-31 67667607
2026-03-31 65918235
2026-06-30 69903819
2026-09-30 68789881

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for VERTEX PHARMACEUTICALS INC held by Provident Investment Management Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 131,577 -9,151 (-6.5%) 6.89% $68,789,881 2026-10-23
Q2 2026 Reduced 140,728 -6,892 (-4.7%) 6.79% $69,903,819 2026-08-11
Q1 2026 Reduced 147,620 -1,638 (-1.1%) 6.55% $65,918,235 2026-05-13
Q4 2025 Reduced 149,258 -4,148 (-2.7%) 6.16% $67,667,607 2026-02-04
Q3 2025 Reduced 153,406 -5,301 (-3.3%) 5.3% $60,079,926 2025-11-19
Q2 2025 Added 158,707 +2,382 (1.5%) 6.04% $70,656,356 2025-08-26
Q1 2025 Added 156,325 +1,259 (0.8%) 7.14% $75,789,487 2025-05-09
Q4 2024 Reduced 155,066 -439 (-0.3%) 5.96% $62,445,078 2025-02-12
Q3 2024 Reduced 155,505 -4,357 (-2.7%) 6.45% $72,322,265 2024-11-12
Q2 2024 Reduced 159,862 -263 (-0.2%) 6.82% $74,930,517 2024-08-07
Q1 2024 Reduced 160,125 -194 (-0.1%) 5.9% $66,933,851 2024-05-14
Q4 2023 Reduced 160,319 -850 (-0.5%) 6.16% $65,232,198 2024-02-12
Q3 2023 Reduced 161,169 -1,060 (-0.7%) 6.18% $56,044,908 2023-11-14
Q2 2023 Reduced 162,229 -815 (-0.5%) 6.04% $57,090,007 2023-08-09
Q1 2023 Added 163,044 +2,317 (1.4%) 5.57% $51,370,273 2023-05-15
Q4 2022 Reduced 160,727 -1,300 (-0.8%) 5.5% $46,414,743 2023-02-13
Q3 2022 Reduced 162,027 -7,328 (-4.3%) 6.01% $46,913,000 2022-11-17
Q2 2022 Reduced 169,355 -17,959 (-9.6%) 5.62% $47,722,000 2022-08-11
Q1 2022 Added 187,314 +2,135 (1.2%) 4.68% $48,883,000 2022-05-16
Q4 2021 Added 185,179 +1,813 (1.0%) 3.67% $40,665,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1903 managers reported VERTEX PHARMACEUTICALS INC for Q3 2026.

Managers reporting VERTEX PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Capital World Investors Reduced 25,966,793 -148,221 1.65% $13,575,850,288 54 qtrs
BlackRock Inc Reduced 23,803,111 -306,262 0.18% $12,444,504,450 9 qtrs
Capital Research Global Investors Reduced 17,814,302 -1,676,335 1.32% $9,313,657,644 15 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 16,595,978 +15,265 0.18% $8,676,543,258 3 qtrs
STATE STREET CORPORATION Added 12,024,456 +152,997 0.18% $6,286,505,841 54 qtrs
Invesco Ltd Added 8,280,998 +237,946 0.34% $4,329,388,595 54 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 6,081,969 +64,121 0.16% $3,165,506,588 54 qtrs
JPMorgan Chase & Co Reduced 5,691,686 -825,914 0.16% $2,997,982,781 54 qtrs
Capital International Investors Added 5,059,186 +364,042 0.55% $2,645,058,681 8 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 4,944,618 +65,631 0.12% $2,585,095,737 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
October 23, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
131,577

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.